Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Dec;29(6):327-42.
doi: 10.1007/s12250-014-3539-2. Epub 2014 Dec 15.

Ocular herpes: the pathophysiology, management and treatment of herpetic eye diseases

Affiliations
Review

Ocular herpes: the pathophysiology, management and treatment of herpetic eye diseases

Lucy Zhu et al. Virol Sin. 2014 Dec.

Abstract

Herpesviruses are a prominent cause of human viral disease, second only to the cold and influenza viruses. Most herpesvirus infections are mild or asymptomatic. However, when the virus invades the eye, a number of pathologies can develop and its associated sequelae have become a considerable source of ocular morbidity. The most common culprits of herpetic eye disease are the herpes simplex virus (HSV), varicella zoster virus (VZV), and cytomegalovirus (CMV). While primary infection can produce ocular disease, the most destructive manifestations tend to arise from recurrent infection. These recurrent infections can wreck devastating effects and lead to irreversible vision loss accompanied by a decreased quality of life, increased healthcare usage, and significant cost burden. Unfortunately, no method currently exists to eradicate herpesviruses from the body after infection. Treatment and management of herpes-related eye conditions continue to revolve around antiviral drugs, although corticosteroids, interferons, and other newer therapies may also be appropriate depending on the disease presentation. Ultimately, the advent of effective vaccines will be crucial to preventing herpesvirus diseases altogether and cutting the incidence of ocular complications.

PubMed Disclaimer

References

    1. Akhtar J, Shukla D. Viral entry mechanisms: cellular and viral mediators of herpes simplex virus entry. FEBS J. 2009;276:7228–7236. - PMC - PubMed
    1. Al-Dujaili L J, Clerkin P P, Clement C, McFerrin H E, Bhattacharjee P S, Varnell E D, Kaufman H E, Hill J M. Ocular herpes simplex virus: how are latency, reactivation, recurrent disease and therapy interrelated? Future Microbiol. 2011;6:877–907. - PMC - PubMed
    1. Anderson J R, Behrens C, Binswanger I A. posting date. HIV Web Study. 2013.
    1. Arvin A M. Varicella-zoster virus. Clin Microbiol Rev. 1996;9:361–381. - PMC - PubMed
    1. Arvin A M. Human herpesviruses: biology, therapy, and immunoprophylaxis. Cambridge; New York: Cambridge University Press; 2007. pp. 1262–1273. - PubMed

MeSH terms

Substances